4D Molecular Therapeutics Presents Interim Results from the
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic...
United States Robert Kim Cagri Besirli David Kirn Kellogg Eye Center American Society Of Retina Specialists
Source: globenewswire.com